FDA Approvals - Biotechs Lose Favor On Wall St. Amid FDA Delays, Generic
Biotechs Lose Favor On Wall St. Amid FDA Delays, Generic Risks (Investor's Business Daily via Yahoo! Finance)
If you pay any attention to the U.S. drug industry, you know that the top players are taking it on the chin for being too big, too slow and too...
NovaDel Announces Clinical Development Strategy to Advance Candidates With Near-Term NDA Submissions (RedNova)
NovaDel Pharma Inc. (AMEX: NVD), today announced a refined clinical development strategy focused on advancing its most mature drug candidates to New Drug Applications (NDAs) with the Food and Drug Administration (FDA).
Noticias Infobolsa / Titulares (InfoBolsa)
Stock 29/06/2007 21:11:00 Business Wire Forward-Looking Statements This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995.